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Abstract 
The world has experienced a pandemic due to novel Severe Acute Respiratory 
Disease Corona Virus-2 (SARS-CoV2) since December 2019. The clinical 
spectrum of the disease known as Coronavirus Disease 2019 (COVID-19) is 
so much wide, starting from an asymptomatic state to paucisymptomatic 
clinical presentation, pneumonia, respiratory failure to even death. 
Supplemental oxygen therapy is essential in managing COVID-19. Also, there 
is sparse evidence regarding use of non-invasive ventilation (NIV) in 
pandemics like SARS-CoV-2. This study reviews the currently available 
methods for respiratory support in COVID-19 with a discussion about using 
these modalieties in the COVID-19 pandemic. 
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Introduction 
Since December of 2019 an outbreak of novel 
Coronavirus disease 2019 (COVID-19) was reported 
and WHO declared a pandemic by 11 March 2020. In 
28 march of the same year more than 200 countries, 
territories or areas has been infected with more than 
510,000 confirmed cases (1). 
The clinical spectrum of this disease could range 
from asymptomatic, mild upper respiratory tract 
infection illness, severe viral pneumonia, respiratory 
failure and even death (2). Most of the reported 
mortalities are due to alveolar damage and respiratory 
failure (3). Therefore, at the end of the clinical 
spectrum, COVID-19 patients require respiratory 
support. Respiratory support aims to maintain adequate 
oxygenation or ventilation to reduce respiratory work 
and to prevent lung injury. This pivotal role can be 
achieved by either increasing FiO2 or helping the 
mechanical respiratory system of the patient to deliver 
more oxygen in to the blood stream (4). 
Adequacy of oxygen delivery (DO2) is essential 
for aerobic metabolism; therefore, “Shock state” is 
defined by tissue hypoxia. COVID-19 interferes with 
uptake of oxygen from inhaled gaseous mixture due to 
alveolar damage with cellular fibromyxoid exudates 
and interstitial mononuclear inflammatory infiltrates 
leading to acute respiratory distress syndrome (ARDS) 
(5). In early stages of ARDS acute oxygen therapy can 
lay an integral role in treatment of tissue hypoxia. 
Therefore, understanding basics of oxygen therapy and 
the devices used are essential for treating patients with 
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COVID-19. 
Non-invasive ventilation (NIV) refers to 
delivery of positive pressure in to the airway for 
ventilation support, without invasive endotracheal 
intubation. NIV has been shown to be effective in acute 
respiratory failure while avoiding complications of 
endotracheal intubation especially ventilator 
associated pneumonia (6). As NIV is proposed as the 
first line treatment in patients with acute respiratory 
failure, NIV in COVID-19 patients might be beneficial 
(7). Besides,  NIV is known as aerosol generating 
procedure, therefore there should be cautions in order 
to minimize spread of the virus (8). 
In this review we have discussed how to 
maintain oxygenation and the rational use of devices in 
patients requiring higher FiO2 and also we have 
discussed the controversies regarding non-invasive 
ventilation (NIV). 
Supplemental Oxygen Support: 
The first line therapy of hypoxemic patient like 
COVID-19 is administration of supplemental oxygen 
(9). Oxygen therapy is defined by administration of 
oxygen at concentrations above room air which is 
20.9% (10). There are numerous devices in order to 
prescribe oxygen. When using these devices some 
cautions has to be applied in order to gain maximal 
efficacy for the patient (11).  As shown in a multi-
center study in Wenzhou, China about 90% of COVID-
19 patients required oxygen therapy (12). General 
principle in providing oxygen for patients with 
COVID-19 is that higher flow may result in risk of 
viral aerosolization (8). There are two types of oxygen 
delivery devices which deliver either the entire (high 
flow) or partial (low flow) ventilator requirements.  
1) Low Flow Oxygen Delivery Devices 
Nasal cannula: FiO2 delivered by nasal cannula 
depends on minute ventilation and oxygen flow rate, 
which would be 1-6 liter/min (FiO2 increases 
approximately 4% per liter flow from 24% to 44%). 
This device is simple, comfortable and convenient and 
prevents rebreathing while allowing talking and eating. 
It may cause local irritation and dermatitis with higher 
flow rates and also as the minute ventilation increases 
the FiO2 prescribed would decrease (13). When 
administering oxygen via nasal cannula we should 
consider that complications like drying of mucosal 
membrane, nasal trauma or epistaxis could happen 
(10). 
Simple (Hudson) Mask: At least 5 liter/min of 
flow rate is required in order to overcome rebreathing, 
also flow rates more than of 10 liters/min would not be 
efficient. The FiO2 provided would be 35% to 60% 
which also depends on flow rate and minute 
ventilation. (approximately 4% per liter of O2) (13). 
Reservoir bag (non-rebreather mask): this 
device is a facial mask combined with a reservoir bag 
with capacity of 600 to 1000 mL and a one-way valve 
connecting these two. These add-ons enable delivering 
higher concentrations of oxygen about 85-90% with 
flow rate of 15 liter/min. The mentioned bag and valve 
is designed so that they could stop rebreathing of 
expired gas. Flow must be sufficient to keep reservoir 
bag from deflating upon inspiration (13). 
 
2) High Flow Oxygen Delivery Devices 
Facial mask with Venturi valve: These devices 
have the benefit of overcoming rebreathing due to high 
flow rates provided by Venturi valves operating by 
Bernoulli principle of jet gas mixing. They are capable 
of providing low concentrations of O2 (24-30%). But 
higher flow rates and wider oxygen jet they can 
provide FiO2 as high as 60%. Their oxygen 
concentration do not depend on minute ventilation 
hence it depends on oxygen flow rate which is 
indicated by each valve and should be followed by the 
manufacturer’s preference (14). The nozzles are color 
coded for desirable concentrations of 24% blue, 28% 
white, 35% yellow, 40% red and 60% green (10). 
High Flow Nasal Cannula: These relatively new 
systems allow humidification and heating the oxygen 
provided for the patient while delivering variable flow 
rates between 1 to 60 Liter/min. Actual FiO2 delivered 
by these devices is not stable. It depends on the flow 
rate, respiratory rate, peak inspiratory flow rate and 
also method of breathing (higher with mouth-open 
breathing than mouth-closed breathing) (11). Their 
FiO2 could range from 24% when using low flows up 
to more than 70% with high flow rates.  although it has 
not yet been described any contraindications, but in 
cases NIV is contraindicated you should reconsider its 
use (15). 
There are limited data regarding use of HFNO 
in pandemics, hence a retrospective cohort study in 
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Wuhan, China, reported mortality of 28% in first 
month of outbreak. In that study about 20% of patients 
receiving HFNO, survived (2, 8). Although early 
invasive ventilation is proposed in some studies, a 
cohort study of Influenza A epidemic showed HFNO 
decreased invasive mechanical ventilation by 45% (8, 
16). Clinical data of 60 severe cases gathered in 
Jiangsu, China, concluded that early NIV and HFNO 
combined with prone ventilation can delay intubation 
and improved hypoxia in COID-19 patients (17). 
The risk of aerosol production when using 
HFNO depends on duration of use, flow rate, patient 
cooperation and sealing of the interface. A well fitted 
interface would minimize aerosol generation (18). On 
the other hand, personal protective equipment (PPE) 
are a critical point when using HFNO (16). Also 
negative pressure ventilation rooms are ideal when 
performing aerosol generating procedure and if not 
applicable normal room with strict door policy should 
be used (8). 
These results are suggesting that if mechanical 
ventilation became scarce, using HFNO would be a 
necessity in order to provide adequate oxygenation for 
these patients (19). Patient selection in this situation 
would be critical. Patients with higher risk factors and 
severe illness, that suggests inevitable mechanical 
ventilation, would not benefit from HFNO (8).  
 
Non-Invasive Ventilation 
Some devices are designed to help ventilation 
and drive force. They can be either invasive also 
known as intubation, or non-invasive ventilation 
(NIV). NIV divides in to two groups;  
Continuous positive airway pressure (CPAP), 
this mode delivers high pressure oxygen by a tight 
fitting mask, attached to a ventilator, in all the times 
during respiration. This cannot ventilate patients, it 
could keep airways and alveolus open during 
ventilation. Its use has been verified in sleep apnea and 
heart failure. Pressure assigned by this device is 
analogous to positive end expiratory pressure (PEEP).  
Bilevel positive airway pressure (BiPAP): This 
mode delivers two different airway pressures, which 
are inspiratory (IPAP) and expiratory (EPAP). EPAP 
is analogous to PEEP on CPAP and IPAP is a higher 
pressure which helps to increase inspiratory effort of 
the patient (22). Initial pressure setting for EPAP is 3 
cmH2O and for IPAP is 10 cmH2O. Then it should up 
titrate in 10-30 minutes to achieve adequate chest 
expansion, IPAP shouldn’t exceed 30 cmH2O (23). 
Other new modes of delivery can have been 
proposed not limited to proportional assist ventilation 
(PAV), average volume assured pressure support 
(AVAPS) and assist/control modes (24). 
Contraindications of NIV are facial anomalies, recent 
upper gastrointestinal surgery, nausea and vomiting, 
airway obstruction, inability to protect airway, life 
threatening hypoxia, confusion and agitation, patient 
refusal, bowel obstruction, and unstable 
hemodynamics.  
In a retrospective cohort by Zhou in Wuhan at 
first month of the outbreak of coronavirus disease 2019 
among 191 patients, about 30% of patients had 
dyspnea described by respiratory rate more than 
24/min. More than half of them supported with 
invasive ventilation and less than half of them were 
supported by non-invasive ventilation the mortality 
rate between these two groups was 92% in NIV 
compared with 96% in intubated patients (2). Xiabo 
Yang and colleagues (18) describe 52 patients with 
COVID19 that was admitted in Wuhan, China, 29 
patients needed mechanical ventilation that 76% of 
whom required invasive mechanical ventilation 
although 24% of whom continue their treatment by 
non-invasive mechanical ventilation. Mortality rate 
among intubated group was 86% versus 57% in NIV 
group. These mortality rate in other study on 29 
patients was 79% in intubated patients versus 86% in 
patients supported by non-invasive ventilation (17). 
Mortality rate was higher in patients with invasive 
Table 1: Pros and Cons of NIV in COVID19 patients with respiratory failure. 
 
Pros Cons 
Non-invasive method Need personnel protection equipment 
Effective in non-severe respiratory failure Need airborne isolated room 
Low rate of mortality Ineffective in severe respiratory failure 
Lower ventilator associated pneumonia (VAP) Barotrauma  
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mechanical ventilation. The exact cause of death is 
unclear. Intubated patients might have more severe 
respiratory symptoms and organ failure but this 
difference in several studies might be due to the 
method of oxygen supply in COVID patients. 
Oxygen therapy is one of the main supportive 
therapies in critically ill patients because most of them 
suffered from organ failure due to hypoxia. Regardless 
of oxygen supply method, early oxygen therapy is 
recommended in various studies (17). Invasive 
mechanical ventilation is recommended in some 
studies. But almost all patients had limited life 
expectancy after intubation. therefore, more effort are 
required in order to evaluate this concept (25). On the 
other hand, sometimes supportive therapy by NIV is 
not a choice because of some inevitable reasons like 
when there is lack of ventilator, fear of contamination 
and uncertainty about intubation(19, 26). 
In some studies, it is not recommended to use 
non-invasive mechanical ventilation for patients with 
COVID-19 (9, 18, 27). The main reasons for their 
concerns are both evidence in support for their 
beneficial aspects, and also the safety properties of 
these devices (8, 16). First of all, there are many 
concerns about wide spread dispersion of the virus as 
it was high in other viruses like Middle East 
Respiratory Syndrome (MERS) (26). Regardless of the 
belief that NIV is an aerosol generating procedure, 
reports show that this method is using all over the 
world in treatment of COVID-19. There are many 
suggestions about using high level of personal 
protection equipment and standard hospital structures 
to make effective negative pressure room during 
treatment with NIV(27) (8). Jonathan Chun-Hei 
Cheung et al., insist on doing aerosol generating 
procedures just in airborne infection isolated room and 
with double glove technique (27). 
The other disadvantage of non-invasive 
ventilation is delayed emergent intubation that may 
expose the staffs with not enough person protection 
equipment. Patients with non-invasive ventilation are 
also at the risk of large tidal volume and barotrauma 
due to high transpulmonary pressure. In patients with 
severe respiratory failure beneficial of oxygen therapy 
by NIV is still questionable. It seems to be better not to 
use NIV for severe respiratory failure (8). On the other 
hand, in recent studies there are evidences in beneficial 
usage of non-invasive mechanical ventilation in non-
severe form of respiratory failure in patients with 
corona virus. These publications suggest that 
acceptable interface fitting mask while using NIV has 
low risk of transmission and cannot create wide spread 
dispersion (28). The other important point in using this 
method is that the patients need close monitoring to 
evaluate if treatment failure would happen or not (26). 
Other advantages of NIV versus intubation are higher 
acceptance of patients and health care providers .In 
some cases with respiratory failure NIV could decrease 
the rate of intubation and its complications like 
ventilator associated pneumonia (20, 21). Advantage 
and disadvantage of respiratory support by NIV is 
shown in Table 1. 
 
Conclusion 
Early oxygen support is advised in every patient 
with COVID-19, in order to achieve maximal benefit 
basic principles of oxygen support should be 
implemented. Each patient should be considered 
unique and the appropriate oxygen support device 
should be selected. HFNO has been shown to be 
effective in maintaining oxygenation while it may not 
have major impact on clinical outcome. HFNO should 
be used with caution due to its ability to spread the 
virus, therefore PPE, negative pressure ventilation 
rooms or strict door protocols and avoidance of 
positive pressure ventilation rooms are mandatory. 
There is concern about viral spread through 
aerosolization by NIV. This concern is questionable as 
recent studies did not find any differences between 
viral spread of NIV versus coughing in patients 
suffering from CVOID-19. Also NIV has been shown 
to reduce VAP and decrease rate of invasive ventilation 
in mild to moderate cases. Therefore, its use is 
recommended in non-severe respiratory failure cases 
with appropriate PPE. 
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